Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04842032
Study type Interventional
Source Kyowa Kirin Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 4
Start date November 1, 2021
Completion date December 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04842019 - Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH Phase 4
Not yet recruiting NCT04872907 - Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT Phase 3
Completed NCT04049877 - Retrospective and Prospective Disease Progression and Quality of Life in XLH
Completed NCT04188964 - Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Phase 1/Phase 2